Document is current

Article History

Received: 10 March 2025

Accepted: 5 April 2025

First Online: 22 April 2025

Declarations

:

: EYA: None. SG: None.TCR: None.Y.O: Consulting fees from Istari Oncology, PharPoint Research; Participation on a Data Safety Monitoring Board or Advisory Board in Actuate, GammaTile, Novocure; other financial or non-financial interests in Blue Earth Diagnostics, BMS, Cantex Pharmaceuticals, Chimerix, CNS Pharmaceuticals, Exelixis, Karyopharm, MimiVax LLC, VBI Vaccines. MRM: None.SY: None.OG: None.M.D.H: Grant support from Florida Department of Health, Grant 22L01. Proton Therapy Cooperative Group of North America (PTCOG-NA) Treasurer (unpaid); Proton Therapy Cooperative Group (PTCOG) Pediatric Subcommittee Co-Chair (unpaid); Proton Collaborative Group (PCG) Executive Council Representative for Miami Cancer Institute (unpaid). RHP: None.DJW: None.CL: None.RT: None.ANG: Honoraria from ViewRay, Inc., Elekta AB, IBA; Ownership interest of Atlantic Health Solutions (uPlan), LLC.MWM: Consultant Deinde Medical and Stryker Medical.MSA: Grants from Seagen, AstraZeneca, BMS, Bayer, Incyte, Pharmacyclics, Novocure, MimiVax, and Merck; consulting fees from Bayer, Novocure, Kiyatec, Insightec, GSK, Xoft, Nuvation, Celularity, SDP Oncology, Apollomics, Prelude Therapeutics, Janssen, Tocagen, Voyager Therapeutics, ViewRay, Caris Life Sciences, Pyramid Biosciences, Varian Medical Systems, Cairn Therapeutics, AnHeart Therapeutics, Menarini Ricerche, Sumitomo Pharma Oncology, Autem therapeutics, GT Medical Technologies, Allovir, Equillium Bio., QV Bioelectronics, and Theraguix; scientific advisory board memberships for Cairn Therapeutics, Pyramid Biosciences, Bugworks, and Modifi Biosciences; data safety and monitoring committee membership for VBI Vaccines; stock shareholder in MimiVax, CytoDyn, Trisalus Lifesciences, and MedInnovate Advisors, LLC.M.P.M.: Consulting Fees from Telix, Zap, Xoft, Kazia Therapeutics, Novocure; Mevion Technological Advisory Board; NRG Brain Tumor Committee Chair; Leadership (unpaid) Board of Directors, Xcision; Stock in Chimerix.R.K.: Honoraria from Elekta AB, Accuray Inc., Novocure Inc., ViewRay Inc., Elsevier Inc., Brainlab, Peerview Institute for Medical Education, and Ion Beam Applications; consulting fees from Kazia Therapeutics, Elekta AB, ViewRay Inc., Castle Biosciences, Novocure Inc.; institutional research funding from Medtronic Inc., Blue Earth Diagnostics Ltd., Novocure Inc., GT Medical Technologies, AstraZeneca, Exelixis, ViewRay Inc., Brainlab, Cantex Pharmaceuticals, Kazia Therapeutics and Ion Beam Applications; support for travel or meeting attendance by Elekta AB, Accuray Inc., Novocure Inc., Peerview Institute for Medical Education, Brainlab, ViewRay Inc.; and participation on an advisory board for Viewray Medical Advisory Board, GT Medical Technologies Data Safety Monitoring Board, Insightec Ltd, Plus Therapeutics, Inc.